by 
Rheumatoid arthritis is a chronic inflammatory disease that causes pain, swelling, and stiffness in the joints. The diagnostic tests play a vital role in early diagnosis and determining appropriate treatment methods for rheumatoid arthritis. Common diagnostic tests for rheumatoid arthritis include biomarker tests, joint imaging, serology tests, and synovial fluid analysis. The biomarker tests measure levels of proteins like rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies in the blood to evaluate rheumatoid arthritis. The global rheumatoid arthritis diagnostic tests market is estimated to be valued at US$ 625.22 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The global rheumatoid arthritis diagnostic tests market is driven by the development of novel biomarkers and integration of molecular diagnostics with conventional tests. Biomarkers play a crucial role in early diagnosis of rheumatoid arthritis as well as predicting treatment response. Researchers are focusing on discovering new biomarkers that can detect the disease in its initial stages to enable prompt treatment intervention. For instance, anti-carbamylated protein (anti-CarP) antibodies and anti-mutated citrullinated vimentin (anti-MCV) antibodies are emerging as promising serological biomarkers for rheumatoid arthritis diagnosis. In addition, advanced molecular diagnostic techniques such as transcriptomics and proteomics are being integrated with conventional tests to gain comprehensive insights into pathogenesis as well as disease progression mechanisms in rheumatoid arthritis patients. Such novel diagnostic approaches are expected to boost the growth of the global rheumatoid arthritis diagnostic tests market during the forecast period.
Market Dynamics:
The development of novel biomarkers and its integration with molecular diagnostics is fueling growth of the rheumatoid arthritis diagnostic tests market. Biomarkers play a crucial role in early diagnosis of rheumatoid arthritis as well as predicting treatment response. Researchers are focusing on discovering new biomarkers that can detect the disease in its initial stages to enable prompt treatment intervention. Advanced molecular diagnostic techniques such as transcriptomics and proteomics are also being integrated with conventional tests to gain comprehensive insights into disease pathogenesis and progression mechanisms in rheumatoid arthritis patients. Such novel diagnostic approaches are anticipated to boost the adoption of rheumatoid arthritis diagnostic tests globally.
Segment Analysis
The rheumatoid arthritis diagnostic tests market is dominated by serological tests sub-segment. Serological tests account for over 60% of market share owing to higher reliability and sensitivity of these tests in detecting rheumatoid arthritis in early stages. These tests detect the presence of anti-CCP antibodies and rheumatoid factor in blood which are highly specific for rheumatoid arthritis.
PEST Analysis
Political: Governments across the world are increasingly funding healthcare systems to facilitate early diagnosis and treatment of rheumatoid arthritis. They are supporting awareness campaigns about benefits of early testing and management of the disease.
Economic: Rising healthcare expenditure coupled with growing per capita income is positively impacting the demand for accurate rheumatoid arthritis diagnostic tests in markets. Additionally, favorable reimbursement policies for diagnostic tests are encouraging patients to opt for testing.
Social: Increasing awareness about rheumatoid arthritis symptoms and available diagnostic options through chronic disease management programs and online health communities is driving more patients to opt for tests. Additionally, growing social stigma related to joint pain and mobility issues is propelling the testing adoption.
Technological: Continuous development of highly accurate testing platforms with capabilities of detecting subtle molecular and cellular level changes associated with rheumatoid arthritis in early stages is boosting the diagnostic rates. Additionally, automated testing instruments with high throughput are improving the efficacy and convenience.
Key Takeaways
The global rheumatoid arthritis diagnostic tests market is expected to witness high growth over the forecast period of 2023 to 2030 supported by rising global disease prevalence.
Regional analysis: North America currently holds the largest share driven by advanced healthcare infrastructure and widespread healthcare insurance. However, Asia Pacific region is poised to thrive at fastest pace owing to improving access to healthcare facilities, expanding patient pool, and increasing medical tourism.
Key players operating in the rheumatoid arthritis diagnostic tests market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., anti-CCP test, Rheumatoid Factor Test, ESR Test. These major players collectively account for over 50% of global market. Additionally, Siemens Healthineers AG, Beckman Coulter, Inc., Euro Diagnostica AB, autoimmune tests, Inova Diagnostics, and Thermo Fisher Scientific Inc. are some of the other prominent players with strong geographical presence and diversified product portfolios.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
